Primary cutaneous diffuse large B-cell lymphoma, leg type (original) (raw)
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) (also termed PCDLBCL, leg type or primary cutaneous DLBCL, leg type) is a cutaneous lymphoma skin disease that occurs mostly in elderly females. In this disease, B cells (a type of lymphocyte) become malignant, accumulate in the dermis (i.e. the layer under the epidermis) and subcutaneous tissue below the dermis to form red and violaceous skin nodules and tumors. These lesions typically occur on the lower extremities but in uncommon cases may develop on the skin at virtually any other site. In ~10% of cases, the disease presents with one or more skin lesions none of which are on the lower extremities; the disease in these cases is sometimes regarded as a variant of PCDLBL, LT termed primary cutaneous diffuse large B-cel
| Property | Value |
|---|---|
| dbo:abstract | Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) (also termed PCDLBCL, leg type or primary cutaneous DLBCL, leg type) is a cutaneous lymphoma skin disease that occurs mostly in elderly females. In this disease, B cells (a type of lymphocyte) become malignant, accumulate in the dermis (i.e. the layer under the epidermis) and subcutaneous tissue below the dermis to form red and violaceous skin nodules and tumors. These lesions typically occur on the lower extremities but in uncommon cases may develop on the skin at virtually any other site. In ~10% of cases, the disease presents with one or more skin lesions none of which are on the lower extremities; the disease in these cases is sometimes regarded as a variant of PCDLBL, LT termed primary cutaneous diffuse large B-cell lymphoma, other (PCDLBC-O). PCDLBCL, LT is a subtype of the diffuse large B-cell lymphomas (DLBCL) and has been thought of as a cutaneous counterpart to them. Like most variants and subtypes of the DLBCL, PCDLBCL, LT is an aggressive malignancy. It has a 5-year overall survival rate of 40–55%, although the PCDLBCL-O variant has a better prognosis than cases in which the legs are involved. Most lymphomas begin in a lymph node, mucosa-associated lymphoid tissue, the spleen, or another lymphoid tissue within the lymphatic system and then may spread to the skin. In these cases the skin is a secondarily site of involvement. PCDLBC, LT is a primary cutaneous lymphoma, i.e. it begins in the skin and then may spread to lymphoid and/or non-lymphoid tissues in virtually any other site. A suspect PCDLBCL, LT that is not limited to the skin at the time of diagnosis should be regarded as some other variant or subtype of the diffuse large B-cell lymphomas. PCDLBC, LT represents 5–10% of all primary cutaneous lymphomas. It is to be distinguished from two other primary cutaneous lymphomas that involve B-cells, primary cutaneous follicle center lymphoma (PCFCL) and primary cutaneous marginal zone lymphoma (PCMZL), as well as from a B-cell lymphoma that at diagnosis may appear to be limited to the skin but often is a systemic disease affecting numerous organs and tissues viz., intravascular large B-cell lymphoma (IVLBCL). These three B-cell lymphomas differ from PCDLBCL, LT in numerous ways but most importantly in their aggressiveness. IVLEBC is, like PCDLBCL, LT, an aggressive disease with a guarded prognosis, but unlike the former disease, is often widely disseminated at presentation. PCFCL and PCMZL, in contrast, are indolent lymphomas with a relatively good prognosis. Distinguishing between these four cutaneous B-cell lymphomas at the time of diagnosis is critical for their appropriate treatment. (en) |
| dbo:complications | Spread to other tissues |
| dbo:medicalDiagnosis | dbr:Biopsy |
| dbo:wikiPageID | 63126652 (xsd:integer) |
| dbo:wikiPageLength | 22484 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1099431458 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Bcl-2 dbr:Prednisone dbr:Epidermis dbr:MicroRNA dbr:Mutation dbr:MYC dbr:Methylation dbr:Monocyte dbr:Primary_cutaneous_follicle_center_lymphoma dbr:Proliferative_index dbr:Biopsy dbr:Blinatumomab dbr:Pathogenic dbr:Rituximab dbr:CD27 dbr:CD30 dbr:CD79a dbr:Varlilumab dbr:Dermatology dbr:Dermis dbr:Interleukin_10 dbr:JAK-STAT_signaling_pathway dbr:Spleen dbr:Anaplasia dbr:Chemoimmunotherapy dbr:Gene_silencing dbr:Oncovin dbr:Monoclonal_antibody dbr:Apoptosis dbr:Lenalidomide dbr:Lumiliximab dbr:Lymph_node dbr:Malignant dbr:Skin_biopsy dbr:Clinical_trial dbr:Programmed_cell_death dbr:Macrophage_polarization dbr:Subcutaneous_tissue dbr:Systemic_disease dbr:Tumor_necrosis_factor_superfamily dbr:CT_scan dbr:Tositumomab dbr:Tumor_suppressor dbr:Liposome dbr:Cutaneous_B-cell_lymphoma dbr:Cutaneous_lymphoma dbr:Cycloheximide dbr:Dacetuzumab dbr:Doxorubicin dbr:European_Organisation_for_Research_and_Treatment_of_Cancer dbr:Nivolumab dbr:Central_nervous_system dbr:Centroblast dbr:Chromosomal_translocation dbr:Chromosome_9 dbr:Germinal_center dbr:Eosinophils dbr:Transcription_factor dbr:Promoter_(genetics) dbr:Hematology dbr:Intravascular_large_B-cell_lymphoma dbr:B_cell dbr:B_symptoms dbc:Lymphoma dbc:Lymphoid-related_cutaneous_conditions dbr:Chimeric_antigen_receptor_T_cell dbr:Survival_rate dbr:IgM dbr:Diffuse_large_B-cell_lymphoma dbr:BCL6 dbc:Non-Hodgkin_lymphoma dbr:Mantle_cell_lymphoma dbr:Bone_marrow dbr:Bone_marrow_examination dbr:CARD11 dbr:CD163 dbr:CD19 dbr:CD20 dbr:CD23 dbr:CD33 dbr:CD3_(immunology) dbr:CD5_(protein) dbr:CD79B dbr:CDKN2A dbr:CHOP_(chemotherapy) dbr:Plasma_cells dbr:Ibritumomab_tiuxetan dbr:Immunotherapy dbr:Interferon_gamma dbr:Metastasis dbr:Ofatumumab dbr:Oncology dbr:Radioimmunotherapy dbr:Radiotherapy dbr:CDKN2B dbr:Mucosa-associated_lymphoid_tissue dbr:Night_sweats dbr:TNFAIP3 dbr:FOXP1 dbr:IRF4 dbr:Immune_system dbr:Immunoblast dbr:Immunostaining dbr:Lymphatic_system dbr:Lymphocyte dbr:Primary_cutaneous_marginal_zone_lymphoma dbr:Myeloid-derived_suppressor_cell dbr:T_cell dbr:PD-L2 dbr:PD-L1 dbr:PAX5 dbr:PIM1 dbr:Skin_condition dbr:Protooncogene dbr:CD40 dbr:PEGylated dbr:PET_scan dbr:Hydroxydaunorubicin dbr:NF-kappa_B dbr:CD10 dbr:CD138 dbr:T-cell |
| dbp:complications | Spread to other tissues (en) |
| dbp:diagnosis | Skin biopsy (en) |
| dbp:field | dbr:Dermatology dbr:Hematology dbr:Oncology |
| dbp:name | Primary cutaneous diffuse large B-cell lymphoma, leg type (en) |
| dbp:prognosis | guarded (en) |
| dbp:symptoms | One or more red/violaceous skin nodules/tumors on the legs and/or uncommonly elsewhere (en) |
| dbp:synonyms | PCDLBCL-LT; PCDLBCL, leg type; primary cutaneous DLBCL, leg type (en) |
| dbp:wikiPageUsesTemplate | dbt:Infobox_medical_condition_(new) dbt:Reflist |
| dct:subject | dbc:Lymphoma dbc:Lymphoid-related_cutaneous_conditions dbc:Non-Hodgkin_lymphoma |
| rdf:type | owl:Thing wikidata:Q12136 dbo:Disease |
| rdfs:comment | Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) (also termed PCDLBCL, leg type or primary cutaneous DLBCL, leg type) is a cutaneous lymphoma skin disease that occurs mostly in elderly females. In this disease, B cells (a type of lymphocyte) become malignant, accumulate in the dermis (i.e. the layer under the epidermis) and subcutaneous tissue below the dermis to form red and violaceous skin nodules and tumors. These lesions typically occur on the lower extremities but in uncommon cases may develop on the skin at virtually any other site. In ~10% of cases, the disease presents with one or more skin lesions none of which are on the lower extremities; the disease in these cases is sometimes regarded as a variant of PCDLBL, LT termed primary cutaneous diffuse large B-cel (en) |
| rdfs:label | Primary cutaneous diffuse large B-cell lymphoma, leg type (en) |
| owl:sameAs | wikidata:Primary cutaneous diffuse large B-cell lymphoma, leg type https://global.dbpedia.org/id/CGD8A |
| prov:wasDerivedFrom | wikipedia-en:Primary_cutaneous_diffuse_large_B-cell_lymphoma,_leg_type?oldid=1099431458&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Primary_cutaneous_diffuse_large_B-cell_lymphoma,_leg_type |
| foaf:name | Primary cutaneous diffuse large B-cell lymphoma, leg type (en) |
| is dbo:wikiPageRedirects of | dbr:PCDLBLCL dbr:PCDLBCL dbr:PCDLBLCL-LT dbr:Primary_cutaneous_DLBCL dbr:Primary_cutaneous_diffuse_large_B-cell_lymphoma |
| is dbo:wikiPageWikiLink of | dbr:Cutaneous_B-cell_lymphoma dbr:PCDLBLCL dbr:B-cell_lymphoma dbr:PCDLBCL dbr:PCDLBLCL-LT dbr:Primary_cutaneous_DLBCL dbr:Primary_cutaneous_diffuse_large_B-cell_lymphoma |
| is foaf:primaryTopic of | wikipedia-en:Primary_cutaneous_diffuse_large_B-cell_lymphoma,_leg_type |